DwightKoeberlMD

Clinical Biochemical Genetics, Clinical Genetics, Pediatric Medical Genetics

Associate Professor/Clinical Genetics

Dr. Koeberl is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
2100 Erwin Rd
Durham, NC 27705
Phone+1 919-620-4467

Fax+1 919-684-0983

America's Best Doctors 2009
Judith Graham Pool Fellowship National Hemophilia Society, University of Washington, 1993
March of Dimes Predoctoral Fellowship 1986
Sigma Xi Research Society Carleton College, 1984
Phi Beta Kappa Carleton College, 1984
National Merit Scholar Carleton College, 1980
Fellow (FAAP) American Academy of Pediatrics
Join now to see all

PubMed

Genetic analysis and multimodal imaging confirm m.12148 T > C mitochondrial variant pathogenicity leading to multisystem dysfunction.
Kinsley Belle, Alexander Kreymerman, Jill L Young, Nirmal Vadgama, Marco H Ji
Molecular Genetics and Metabolism. 2025-03-01
The attenuated hepatic clearance of propionate increases cardiac oxidative stress in propionic acidemia.
You Wang, Suhong Zhu, Wentao He, Hannah Marchuk, Eva Richard
Basic Research in Cardiology. 2024-12-01
Staying on target in gene and cell therapy.
Rory Bricker-Anthony, Dwight D Koeberl, Gerald S Lipshutz, Fabiana Perna
Molecular Therapy. 2024-09-04

Journal Articles

Beta2 agonists enhance the efficacy of simultaneous enzyme replacement therapy in murine pompe disease
Koeberl DD, Li S, Dai J, Thurberg BL, Bali D, and Kishnani PS, Mol Genet Metab, 1/1/2012
Immunodominant liver-specific expression suppresses transgene-directed immune responses in murine Pompe disease
Zhang P, Sun B, Osada T, Rodriguiz R, Yang XY, Luo X, Kemper AR, Clay TM, Koeberl DD, Hum Gene Ther, 1/1/2012
Correction of multiple striated muscles in murine Pompe disease through adeno-associated virus- mediated gene therapy
Sun,B, Young SP, Li P, Di C, Brown T, Salva MZ, Li S, Bird A, Yan Z, Auten R, Hauschka SD, and Koeberl DD, Mol Ther, 1/1/2008
Enhanced response to enzyme replacement therapy in Pompe disease following the induction of immune tolerance
Sun B, Bird A, Young SP, Kishnani PS, Chen YT, and Koeberl DD, Am J Hum Genet, 1/1/2007
Adjunctive Beta2-agonists reverse neuromuscular involvement in murine Pompe disease
Li S, Sun B, Nilsson MI, Bird A, Tarnopolsky MA, Thurberg BL, Bali D, Koeberl DD, FASEB
Join now to see all

A New Twist on an Old Hormone Leads to First Drug for a Type of Liver DiseaseAugust 12th, 2024
AskBio Gets $235 Million in Gene Therapy SupportApril 12th, 2019
AskBio Partners with TPG and Vida VenturesApril 11th, 2019
Join now to see all

Phase 1/2 Study of clenbuterol for the treatment of Pompe diseaseFood and Drug Administration2013–Present
Clinical Trial Planning in Pompe DiseaseNational Institutes of Health2013–2014
Enhanced muscle-targeted gene therapy for Pompe diseaseMuscular Dystrophy Association2012–2014
Mechanisms For Immune Tolerance In Pompe DiseaseEunice Kennedy Shriver National Institute Of Child Health &Human Development2009–2010
Gene Delivery To Striated Muscle By Systemic AAV VectorsNational Heart, Lung, And Blood Institute2006–2010